Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors.

NCT06877650 is registered in ClinicalTrials.gov with Shanghai JMT-Bio Inc. as lead sponsor.

NCT NCT06877650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06877650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors.
Lead sponsor
Shanghai JMT-Bio Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 11, 2025
Completion date
March 30, 2029
Enrollment
436 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant tumors